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than had been expected without treatment. The adult height 
achieved by the patients also treated with GnRH analog was 
not different from those who received IGF-I therapy alone. 
There were no new safety signals identified in these patients, 
a subset of those previously reported.  Conclusion: Long-
term therapy with IGF-I improves adult height of patients 
with severe IGFD. Most patients did not bring their heights 
into the normal adult range.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Recombinant human insulin-like growth factor-I 
(IGF-I) replacement therapy has been evaluated for chil-
dren with severe IGF-I deficiency (IGFD), and is ap-
proved for this specific indication [height SD score  ≤ –3, 
and IGF-I SD score  ≤ –3 for the United States, or IGF-I 
<2.5th percentile for the European Union, and normal or 
elevated growth hormone (GH)]  [1, 2] . Most, if not all, of 
the growth-promoting effects of GH in humans occur 
through stimulation of IGF-I production, both by the liv-
er and other tissues  [3] . Therefore, a severe deficiency in 
IGF-I production can be expected to result in profound 
growth retardation. Severe IGFD can be due to a variety 
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 Abstract 
 Background: Treatment with recombinant human insulin-
like growth factor-I (IGF-I) stimulates linear growth in chil-
dren with severe IGF-I deficiency (IGFD).  Aims: To evaluate 
the efficacy and safety of treatment with IGF-I in patients 
with severe IGFD treated until adult or near-adult height. 
 Methods: Twenty-one children with severe IGFD were
treated until adult or near-adult height under a predomi-
nantly open-label design. All patients were naive to IGF-I.
Recombinant human IGF-I was administered subcutane-
ously in doses between 60 and 120 μg/kg twice daily. Nine 
patients received additional therapy with gonadotropin-
releasing hormone (GnRH) analog for a mean period of 
2.9 ± 1.8 years.  Results: Mean duration of treatment was 
10.0 years. Mean height velocity increased from 3.1 cm/year 
prior to treatment to 7.4 cm/year during the first year of 
treatment. Height velocities during the subsequent years 
were lower, but remained above baseline for up to 12 years. 
Cumulative mean Δ height SD score at (near) adult height 
was +2. The observed mean gain in height was 13.4 cm more 
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of causes, including – but not limited to – defects in GH 
action, either at the GH receptor or post-receptor signal-
ing level  [4, 5] . Prior reports have shown that IGF-I ther-
apy can stimulate growth in children who have severe 
(primary) IGFD due to GH receptor abnormalities or GH 
insensitivity, and in those who have developed GH-neu-
tralizing antibodies to GH therapy  [1, 6–9] . However, the 
effect of such therapy with IGF-I on adult height has been 
assessed in only a few patients  [1] . We now report the 
adult and near-adult height of a cohort of 21 children 
treated for a mean duration of 10.0 years.
 Subjects and Methods 
 Subjects 
 Twenty-one children with severe IGFD were diagnosed by pe-
diatric endocrinologists participating in the GH insensitivity syn-
drome (GHIS) collaborative group, and were referred to one of two 
centers. All patients, naive to therapy with IGF-I, were studied ei-
ther at Cincinnati Children’s Hospital Medical Center or the Uni-
versity of North Carolina at Chapel Hill. The study was conducted 
in accordance with national and international ethical and regula-
tory standards. The experimental protocol and informed consent 
documents were reviewed and approved by the institutional re-
view boards of both participating sites. Informed consent and as-
sent were obtained respectively from the parents and, when appli-
cable, the patients. Preliminary data from these subjects have been 
reported previously  [1, 7] . This report describes 21 of the study 
subjects with severe IGFD who received continuous treatment 
with IGF-I until (near) adult height. The initial study entry criteria 
were: age older than 2 years, height SD score <–2 for age and sex, 
IGF-I serum concentration SD score <–2 for age and sex, growth 
rate <50th percentile for age and evidence of GH resistance/insen-
sitivity. The GH insensitivity was further confirmed as failure to 
increase serum IGF-I concentration by more than 50 ng/ml after 
4 daily subcutaneous GH injections of 0.1 mg/kg. For those pa-
tients with GHIS due to a proven or presumed GH receptor defect, 
random or stimulated GH concentrations were  ≥ 10 ng/ml. Chil-
dren who had developed growth-attenuating antibodies during 
GH treatment all had antibodies with a GH-binding capacity 
>10 μg/ml. Children were excluded if they had a prior or active 
malignancy, major organ dysfunction, were on treatment with 
medications that would diminish growth, or had clinically signifi-
cant abnormalities of cardiac function or rhythm. The different 
subcategories of patients are described in  table 1 . Of the 21 pa-
tients, 16 had a diagnosis of GHIS leading to severe primary IGFD. 
In 6 of them a molecular defect of the GH receptor was identified. 
In 10 other patients (GHIS-clinical) no genetic testing was done. 
Five of the 21 patients had GHIS due to a GH gene deletion leading 
to severe secondary IGFD. Of the latter group, 3 had prior short-
term exposure to GH therapy.
 Medications 
 Recombinant human IGF-I (mecasermin, Increlex ® ) was pro-
vided by Genentech, Inc. (South San Francisco, Calif., USA) at 
first, later by Tercica, Inc. (Brisbane, Calif., USA), and then by
Ipsen Biopharmaceuticals, Inc. (Basking Ridge, N.J., USA). Nine 
of the patients also received gonadotropin-releasing hormone 
(GnRH) analog (leuprolide acetate, goserelin, or triptorelin) dur-
ing a portion of the treatment period, in order to delay puberty.
 Study Procedures 
 Subjects began treatment at an IGF-I dose of 40 μg/kg subcu-
taneously twice a day. The dose was increased by 40-μg/kg incre-
ments, usually within a 2-week period, to 120 μg/kg subcutane-
ously twice a day. At the study inception, some children received 
lower doses (40–80 μg/kg twice daily) for the first several months. 
Two subjects were treated with a higher dose of IGF-I (150 μg/kg 
twice daily) during some of their pubertal years. Subjects were 
evaluated at regular intervals: monthly during the first year of 
treatment, bimonthly during the second year, every 3 months for 
Table 1.  Patient subcategories based on underlying diagnosis
Patients (n = 21) Clinical or molecular diagnosis
GHIS with proven GH





Homozygous nonsense mutation in exon 7 (c.703C>T) causing a stop codon (p.Arg217X) in
2 patients
Homozygous nonsense mutation in exon 4 (c.181C>T) causing a stop codon (p.Arg43X) in 2 patients
Homozygous missense mutation in exon 6 (c.509A>G) (p.Asp152Gly)
Heterozygous splice mutation in exon 4 (c.266+1G>A) (p.Asn28ArgfsX41) (exon 4 skipping)
GHIS-clinical (n = 10) No genetic testing done
GH receptor deficiency phenotype with undetectable GH binding protein
Antibodies to GH (n = 5) GH gene deletion type 1A
 The patients with proven GH receptor defect had their diagnosis of GHIS confirmed by genetic testing. The GHIS-clinical patient 
group did not undergo genetic testing, but all had the GH receptor phenotype and fit the study inclusion criteria (including extremely 
low or undetectable GH binding protein) – they had presumed GH receptor deficiency.
c = Coding DNA sequence; p = protein sequence; X = stop codon.
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years 3 and 4, and twice per year thereafter. Scheduled study visits 
included review of the interval medical history and a recording of 
adverse events, anthropometry, and physical examination. The 
height measurements were obtained using a wall-mounted stadi-
ometer. Radiology and laboratory assessments included a radio-
graph of the left hand and wrist for bone age (BA), read centrally 
at the Fells Institute, Yellow Springs, Ohio (now part of Lifespan 
Health Research Center, Dayton, Ohio, USA) using the FELS 
method  [10] . Whole-body bone mineral density (BMD) and fat 
mass measurements were done using dual-energy X-ray absorpti-
ometry (DXA, QDR-1000; Hologic, Inc., Waltham, Mass., USA). 
Echocardiography was done on a yearly basis, using a Sonos 1500 
cardiac ultrasound machine (Hewlett-Packard Co., Andover, 
Mass., USA). Before therapy, after 6 and 12 months, and every year 
of treatment thereafter, measurements of kidney and spleen were 
obtained by ultrasonography. Hematological indices, serum 
chemistry panel, glucose, insulin, hemoglobin A 1c (HbA 1c ), lipids, 
calcium, phosphorus, liver enzymes, thyroid function tests, IGF-I, 
and insulin-like growth factor binding protein-3 (IGFBP-3) were 
monitored throughout the study period.
 Efficacy Endpoints and Statistics 
 The 21 subjects analyzed in this study make up a subset of pa-
tients from a larger cohort previously reported on  [1, 7] . Adult/
near-adult height and annual height velocity were the primary ef-
ficacy endpoints. Height SD score was computed using the Centers 
for Disease Control and Prevention (CDC) age- and gender-de-
pendent means and SD scores  [11] . Because heights were not al-
ways measured at the exact 1-year intervals, some annual heights 
were imputed by interpolation using the closest dates before and 
after the anniversary of treatment initiation. Adult/near-adult 
height was defined as and evaluated in all subjects whose most re-
cent BA was at least 16 years for males and 14 years for females. 
The adult height that subjects might have reached without IGF-I 
treatment was predicted using the Laron syndrome growth charts, 
which constitute a reference range for patients with GH receptor 
abnormalities  [12] .
 Height velocity during each year of treatment was compared 
with pretreatment height velocity using a two-sided paired t test at 
a significance level of 0.05.
 Results 
 Effects of IGF-I Treatment on Growth, Adult Height 
and Body Composition 
 Some of the baseline characteristics are displayed in  ta-
ble  2 . The mean duration of treatment was 10.0 years 
(range 3.6–19.3). The average dose of IGF-I was 113 μg/kg 
given twice daily. Treatment with IGF-I stimulated linear 
growth independent of the degree of shortness or diagnos-
tic category. The mean baseline height velocity (3.1 cm/
year) increased to 7.4 cm/year during the first year of 
treatment (p < 0.0001). Although the mean growth ve-
locities after the first year of therapy were lower, they re-
mained above baseline for up to 12 years of therapy 
( fig. 1 a). Mean height velocity during the second year of 
therapy was 5.6 cm/year and ranged from 3.9 to 5.0 cm/
year during years 3–12. The mean change in height SD 
score at (near) adult height was +1.9 (range +0.1 to +4.7). 
There was significant variability in the change in height 
SD score, in the sense that 9 patients improved their height 
SD score, at final analysis, with +2.0 or more, whereas 12 
patients only had an improvement in height SD score by 
+1.7 or less.  Figure 1 b illustrates the cumulative Δ height 
SD score per study year. The individual growth curves for 
height are shown in  figure 2 a and b for respectively 12 
males and 9 females. Review of the individual growth 
curves shows that, after initial catch-up growth, linear 
growth is parallel to the CDC normative growth curves for 
the US population. Only 3 patients reached a height with-
in the normal range (i.e. SD score –2 or above). Most oth-
er patients still improved their height but did not experi-
ence continued catch-up growth. When the patients with 
GH receptor deficiency (proven or presumed GH receptor 
defect) were compared to the patients with GH gene de-
letion, the former group was slightly younger (mean ages 
7.1 versus 8.4 years) at the beginning of therapy. They 
were also taller: mean height SD score was –6.2 versus 
–8.0, respectively, but mean time on IGF-I therapy was 
about 22 months longer: 10.5 versus 8.7 years. Despite this,
mean Δ height SD scores were similar: +1.9 for the GH 
receptor deficiency subgroup, versus +1.7 for the GH gene 
deletion subgroup. However, this translated to a change
in height minus the expected change without treatment of 
15.1 ± 8.2 cm for the GH receptor deficiency subgroup ver-
sus 7.9 ± 8.5 cm for the GH gene deletion group.
 Only 1 patient had onset of puberty prior to commenc-
ing IGF-I therapy (thelarche by 12 years). When we ob-
served that several of our patients began puberty at a nor-
mal age, this led to a decision to introduce therapy to pro-
Table 2.  Baseline characteristics for 21 subjects with severe IGFD 
treated with recombinant human IGF-I until adult/near-adult 
height
Characteristic n (%) Mean ± SD
GH receptor deficiency (or GHIS) 16 (76)
GH gene deletion + GH antibodies 5 (24)
Female 9 (43)
Age, years 7.4 ± 4.7
Bone age, years 4.9 ± 3.5
Height SD score –6.6 ± 2.1
Weight for age SD score –7.2 ± 5.7
Pretreatment height velocity, cm/year 3.1 ± 2.0
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long the time for growth. Therefore, 9 subjects were also 
treated with GnRH analog therapy (on average for 
2.9 ± 1.8 years). These patients had similar baseline means 
for chronological age (CA) (7.7 years) and height SD 
score (–6.3) as the patients who were treated solely with 
IGF-I (7.2 years, height SD score –6.8). Both these sub-
groups showed a similar response for Δ height SD score: 
+2.0 ± 1.6 versus +1.8 ± 0.8, respectively.
 The adult height that subjects might have reached 
without IGF-I treatment was predicted using the Laron 
syndrome growth charts. We assumed that the growth of 
our patients, if left untreated, would occur at an average 
rate as reported for other untreated Laron syndrome pa-
tients  [12] . The height each subject gained – relative to the 
expected height gain in absence of treatment – is shown 
in  figure 3 . The mean gain in height was, on average, 
13.4 cm more than expected without treatment. Again, 
the great variability in treatment response is seen: 11 pa-
tients improved their adult height by 15 cm or more, 
whereas 10 other patients’ adult height was only im-
proved by 11 cm or less.
 Statural growth was accompanied by weight gain. The 
mean SD score for weight changed from –7.2 (±5.7) at 
baseline to –2.7 (±3.0, range –9.2 to +1.5) at the end of the 
IGF-I therapy. Mean body mass index SD score at the be-
ginning of treatment was –0.3 ± 1.0 and increased in most 
patients, so that the mean body mass index SD score at 
treatment discontinuation was +0.5 (±1.2, range –2.0 to 
+2.2, n = 21). The total body fat percentage, as measured 
by DXA, increased from 30.1 ± 7% (range 18.7–46.4), 
when measured at the start of therapy, to 35.1 ± 7% (range 
23.6–50.6) at the last measurement (n = 18). The Δ% fat 
(whole-body) by DXA was +5.1 ± 4.2 (range –5.7 to +14.4) 
over 9.2 years of IGF-I therapy. At the same time, the 
whole-body lean tissue by DXA decreased form 67.5 ± 7.1% 
(range 50.8–71.8) to 62.0 ± 6.9% (range 46.5–72.5).
 Effects on Bone Maturation and Organ Growth 
 Skeletal maturation was delayed before IGF-I therapy: 
average CA was 7.4 years, while average BA was 4.9 years. 
At the time of the last BA assessment, the average CA




































































































 Fig. 1.  a Pretreatment and on-treatment height velocity for the
21 patients with severe IGFD treated with recombinant human 
IGF-I until (near) adult height. The numbers above each bar in-
dicate the numbers of patients per treatment period (with the declin-
ing numbers of patients representing longer treatment for few-
er patients, not patient drop-out prior to (near) adult height).
 b Cumulative Δ height SD score for the 21 patients with severe 
IGFD treated with recombinant human IGF-I until (near) adult 
height. The numbers above each bar indicate the patient numbers 
per treatment period (with the declining numbers representing 
longer treatment for fewer patients, not patient drop-out prior to 
(near) adult height). 
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15.9 years. The mean BA-to-CA ratio changed from 0.6 
at baseline to 0.9 at the end of the IGF-I therapy. How-
ever,  figure 4 illustrates that the skeletal maturation typi-
cally progressed in accord with the advancing CA during 
therapy. It should be noted that 9 patients were on aver-
age 2.9 ± 1.8 years on treatment with GnRH analogs (the 
duration of GnRH analog treatment varied from 0.6 to 
6.4 years). It is possible that patients within this subgroup 
would have experienced a more rapid skeletal maturation 
had they received IGF-I therapy alone. A subanalysis of 
those treated only with IGF-I (n = 12) yielded a mean 
change in BA of 10.9 ± 3.7 years over a treatment period 
of 9.6 ± 3.6 years. This contrasts with a change in BA of 
11.0 ± 5.0 years over 11.0 ± 5.5 years of therapy for the 
GnRH + IGF-I group (n = 9), with a mean ΔBA/ΔCA of 
1.19 ± 0.3 versus 1.05 ± 0.1, respectively ( fig. 4 ).
 The effect of IGF-I therapy on whole-body BMD was 
measured by DXA (Hologic). Before therapy, BMD SD 
score was at or below –2 for several patients. There was a 
lot of variation in the observed BMD increments (online 
suppl. fig.  1; for all online supplementary material, see 
www.karger.com/doi/10.1159/000351958). Several pa-
tients had significant increases in BMD – beyond what 
was expected based on growth alone. Some of the ob-
served changes in BMD may represent the effect of in-
creased bone volume, a well-known caveat of BMD assess-
ment with DXA. However, slowing of the bone mineral-
ization was not observed, even with the 9 patients treated 
concurrently with GnRH analog therapy included.
 Renal growth data were available in 11 males and 8 fe-
males, with first ultrasonography done at or near the time 
of IGF-I treatment initiation. Renal size and growth, in 
function of height, is shown in  figure 5 (using the mean for 
the left and right renal lengths). The initial examinations 
revealed renal lengths that were low for age but low-nor-
mal for height. Kidney size increased during IGF-I treat-
ment, and 6 patients (3 males, 3 females) had a renal length-
for-height SD score at or above +2 at completion of IGF-I 






























































 Fig. 2.  a Individual growth during IGF-I therapy for 12 male pa-
tients, compared with the US National Center for Health Statistics 
standards (upper shaded area) and the mean ±2 SD for height for 
untreated Laron syndrome patients (lower shaded area). The 
growth curves for Laron syndrome constitute a reference range
for patients with presumed GH receptor abnormalities  [12] . 
 b Individual growth during IGF-I therapy for 9 female patients, 
compared with the US National Center for Health Statistics stan-
dards (upper shaded area) and the mean ±2 SD for height for un-
treated Laron syndrome patients (lower shaded area). The growth 
curves for Laron syndrome constitute a reference range for pa-
tients with presumed GH receptor abnormalities  [12] . 
 Backeljauw  /Kuntze  /Frane  /Calikoglu  /
Chernausek  
 
 Horm Res Paediatr 2013;80:47–56 
DOI: 10.1159/000351958
52
therapy. Three of these patients were considered good re-
sponders and achieved an adult height SD score at or above 
–2; the other 3 patients did not have the same favorable 
growth response. No structural abnormalities of the kid-
neys were noted by ultrasound. Renal function remained 
normal, by determination of normal serum electrolytes 
and creatinine clearance (mean 137 ± 29 ml/min/1.73 m 2 , 
n = 18), while urinalyses did not yield proteinuria.
 Spleen growth was also followed throughout the treat-
ment period for 19 of the subjects (11 males, 8 females). 
Spleen length SD score for age was computed using the 
norms from Rosenberg et al.  [13] . At baseline, average 
spleen length was small (12/19 patients had a spleen 
length SD score <–2) and an increase in spleen length was 
observed for the majority of patients. However, nearly all 
patients had spleen sizes within the normal range at the 
end of treatment. Only 1 subject had a spleen length SD 
score for age >+2 at the end of therapy. This patient ex-
perienced most of the spleen growth during the first 
2 years of treatment and further growth occurred parallel 
with normal spleen growth during the remaining treat-
ment years.
 Effects on Facial Growth 
 Cephalometric investigations, to evaluate the growth 
of the facial bony structures, are available for the first 
6 years of IGF-I treatment in a subset of 8 patients. Before 
therapy, these patients had reduced facial dimensions 
with a small, retrognathic mandible and maxilla. After 
6 years of therapy with IGF-I, most patients were still be-
hind with their craniofacial development, but both linear 
and angular craniofacial parameters had improved. There 
did not appear to be any evidence of acromegaloid growth. 
The changes noted in the facial bones were accompanied 
by growth of the soft tissues of the face, which was more 
obvious when the patients were undergoing pubertal 
changes. The details of the cephalometric studies are the 
topic of a separate paper.
 Effects on Cardiac Function 
 The effect of IGF-I therapy on cardiac function was 
followed by echocardiography and data were available on 
19 patients. Normal intracardiac anatomy and ventricu-
lar function was observed in 15 patients. One patient had 


























































Did not receive GnRH analog
8 10 12 14
Change in chronological age (years)
16 18
 Fig. 3. Change in height achieved at the end of IGF-I therapy for 
21 patients with severe IGFD, relative to their expected change in 
height, based on the assumption that the patients would have 
grown equivalent to untreated patients with Laron syndrome
 [12] . The dotted horizontal line indicates a mean gain in height
of 13.4 cm more than expected without treatment. The squared 
dots or triangles indicate GH gene deletion patients. 
 Fig. 4. Change in BA versus change in CA for 21 patients with near-
adult/adult height. The line in the figure shows the regression line 
using all subjects as a single group. 
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Another patient had a small patent foramen ovale (not 
detected at baseline) with left-to-right shunting, plus 
transient mild mitral insufficiency. Neither finding was 
thought to be related to the IGF-I therapy. Two other pa-
tients were noted with tricuspid insufficiency at their last 
echocardiogram. Three of the study participants were 
noted to have supranormal left ventricular systolic per-
formance at one or more of their follow-up echocardio-
gram tests, but subsequently were described as having 
this finding normalized.
 Laboratory Measurements 
 As reported previously, there were frequent occur-
rences of hypoglycemia both before and after institution 
of IGF-I therapy  [1] . However, the frequency of hypogly-
cemic events did not increase with IGF-I therapy. Normal 
insulin concentrations were observed when measured in 
a subset of patients during the first 2 years of therapy 
(mean 5.3 ± 4.0 μU/ml at year 2). HbA 1c concentrations 
also remained normal during the first 4 years of therapy 
(4.9–5.5%, normal: 4.4–6.1%, n = 18). At last measure-
ment the mean HbA 1c was 4.9% (3.7–5.7%, n = 18). This 
excluded the value for 1 patient, treated for a total of ap-
proximately 12 years, who developed type 2 diabetes mel-
litus during the last year of therapy (HbA 1c of 9.1% at 
diagnosis).
 Mean serum cholesterol was 157.4 ± 30.8 mg/dl at 
baseline (n = 18), 187.9 ± 27.8 mg/dl at 10 years of thera-
py (n = 8), and 173.3 ± 50.6 mg/dl at year 15 (n = 4). The 
total cholesterol ranges were 104–226, 138–228, and 115–
238 mg/dl, respectively. Although in the normal range for 
most subjects, a modest increase in cholesterol was thus 
noticeable for some patients. Triglyceride concentrations 
were also measured higher in some individual patients 
over time: baseline mean triglyceride concentration was 
69.9 ± 29.3 mg/dl (range 20–141, n = 18), and increased 
to 122.5 ± 34.2 mg/dl at 10 years (range 89–193, n = 8), 
and 93.0 ± 23 mg/dl at year 15 (range 73–118, n = 4).
 Serum electrolytes, urea nitrogen, creatinine, albumin, 
total protein, liver transaminases, and bilirubin remained 
normal throughout the study. Lactate dehydrogenase 
(LDH) was normal at baseline (mean 290.7 ± 65 IU/l, 
n = 16, mean age 6 years) and varied appropriately with 
age (mean LDH of 222.6 ± 46.7 IU/l at laboratory year 4, 
mean age 11 years, n = 14). There were some patients, 
later into treatment, who had isolated mild LDH eleva-
tion (range 445–602, n = 3, year 15). Thyroid-stimulating 
hormone remained normal for all patients in each study 
year. Hematologic parameters were also normal, but we 
observed an increase in red cell indices over the course of 
the study, likely due to increasing age and androgen effect 
(adrenarche and/or puberty).
 Adverse Events 
 The adverse events of relevance are listed in online 
suppl. table 1. We did not observe any new such adverse 
events compared with what was previously reported for 
the larger patient population  [1] .
 Discussion 
 Prior studies, further substantiated by isolated case re-
ports, have shown that IGF-I is effective in promoting 
statural growth in children with severe IGFD  [1, 6–9, 14–
16] . The present study defines the clinical course for such 
children undergoing long-term treatment until (near) 
adult height is reached. We have found, as have others, 
that the first-year growth response is typically close to a 
near tripling of the baseline height velocity with optimal 
dosing of IGF-I. In fact, our reported first-year height ve-
locity was likely conservative because 3 patients were 
drawn from an initial study protocol where they received 





















 Fig. 5. Kidney length (using the mean for right and left renal 
lengths) versus height in patients with adult/near-adult height af-
ter long-term therapy with IGF-I. Solid lines represent kidney 
growth from first to last observation for each patient. Dashed 
curves indicate normal mean and mean ±2 SD scores, based on 
Han and Babcock  [38] . 
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active treatment for less than the full year (either 6 or 9 of 
the 12 months). Consequently, their mean dose used dur-
ing the first year of therapy (90 μg/kg/dose twice daily) 
was about 25% less than the recommended maximum 
dose (120 μg/kg/dose twice daily). Omitting these 3 pa-
tients from calculation results in a first-year height veloc-
ity of 7.6 cm/year (compared to 7.4 cm/year). We also 
found that the growth-promoting effects of IGF-I persist 
for many years thereafter. Our subjects grew at approxi-
mately normal height velocities after the first 2–3 years of 
IGF-I treatment. With a growth rate that merely remained 
close to the normal range, they had no additional catch-
up growth after the initial years and most patients did not 
achieve adult heights in the normal range. Nevertheless, 
their adult heights are greater than expected – based on 
previously reported untreated patients – as they contin-
ued to grow well for their primary diagnosis  [12] . One 
caveat regarding the method used to estimate expected 
adult height (without IGF-I treatment) is that the Laron 
syndrome curves are based on a limited number of pa-
tients and extrapolation of height gain over that expected 
may not be entirely applicable. In addition, Laron syn-
drome growth charts do not account for differences in 
patients’ ethnicity or underlying genetic diagnosis either. 
However, given the rarity of the conditions associated 
with severe IGFD, it is still the best information available 
 [12] . Though the positive effects of IGF-I treatment are 
indisputable, the overall growth response in severe IGFD 
patients to long-term IGF-I therapy remains below what 
has been observed when GH-deficient patients are treat-
ed with GH, and in whom a normal adult height is often 
achieved  [17] . There are several potential explanations 
for this. First, the actions of IGF-I involve both endocrine 
as well as paracrine/autocrine mechanisms  [18, 19] . With 
subcutaneously administered IGF-I therapy, we mainly 
restore the endocrine component of the GH/IGF-I axis. 
Because locally produced IGF-I is crucial for optimiza-
tion of linear growth, the therapeutic effect of exogenous-
ly administered IGF-I is limited. Second, studies of ge-
netically altered mice have clearly shown the importance 
of both GH and IGF-I in postnatal growth, with synergis-
tic as well as overlapping functions  [20] . This may or may 
not exactly correlate with findings in humans, but, in our 
patients, the direct actions of GH remain absent during 
IGF-I monotherapy. Third, the subjects have very low 
concentrations of IGFBP-3 and acid-labile subunit, which 
are unaltered during IGF-I therapy  [7] . Thus, the thera-
peutic exposure to IGF-I may be reduced in this situation 
because the clearance of exogenously administered re-
combinant human IGF-I is accelerated. Finally, a compo-
nent of decreased compliance may also have contributed 
to this diminished treatment response. For certain pa-
tients, intermittently throughout the duration of the 
study, there were periods when adherence to the treat-
ment recommendations was suboptimal.
 Puberty is typically delayed in untreated patients with 
GH receptor deficiency  [21] . This was also seen within 
this patient cohort, as only 1 of the subjects had onset of 
puberty prior to when IGF-I therapy was started. We then 
observed that several of our patients began puberty at a 
normal age, prompting the introduction of GnRH analog 
therapy to prolong the time for growth. This effect of 
IGF-I on pubertal maturation has been reported  [22, 23] 
and is consistent with the observation that GH therapy 
shortens the duration of puberty in GH-deficient patients 
 [24] . In this study, the patients additionally treated with 
GnRH analog therapy had a slightly better response (sim-
ilar Δ height SD score with less BA change) than those 
patients treated with IGF-I alone, even though the addi-
tional GnRH analog treatment was begun relatively late 
in the course of puberty for some. We also observed a 
slowing of the height velocity in some patients while on 
GnRH analog therapy, which partially resolved when the 
IGF-I dose was increased to 150 μg/kg/dose twice daily. 
This has been observed in a patient with Laron syndrome 
who experienced an almost complete arrest of growth 
during similar combination treatment  [16] . Combined 
treatment with IGF-I + GnRH analog therapy still may 
improve height outcome in IGFD patients if such therapy 
is started at the onset of puberty. Furthermore, we did not 
observe additional catch-up growth at the onset of pu-
berty. This may again be related to an ongoing lack of di-
rect GH effect, as it has long been established that sex 
steroids exert their full growth-promoting action only in 
the presence of normal GH concentrations  [25] .
 Our long-term observations raise no new concerns 
about the frequency or nature of adverse effects of IGF-I 
treatment in children with severe primary IGFD. We ob-
served a modest gain in fat mass as previously reported  [6, 
7] . This may be a result from intermittent, high free IGF-I 
concentrations after each injection. The insulin-like effect 
of IGF-I on adipocytes, stimulating fat cell growth/lipo-
genesis, has been observed only at high IGF-I concentra-
tions and is believed to be mediated via cross-reactivity 
with the insulin receptor, as IGF-I receptors are not pres-
ent on adipose cells  [26–28] . We did not find overgrowth 
of specific organs for which there had been a concern 
based on data in rats treated with IGF-I  [29] . Heart, kid-
neys and spleen underwent age-appropriate changes in 
most patients. As described, several patients demonstrat-
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ed more robust renal growth. Because some of these pa-
tients also had better linear growth, it is possible that lon-
ger duration of IGF-I therapy, better compliance, or in-
creased IGF-I sensitivity affected these patients’ renal 
growth. Hypoglycemia, documented or reported based on 
clinical suspicion, was frequent but not different than pre-
viously reported and often due to the underlying condi-
tion rather than the IGF-I treatment  [1] . The appearance 
of benign intracranial hypertension has been previously 
reported both during GH therapy and therapy with IGF-I 
 [30–32] . The mechanism for this is most likely an increase 
in the production of cerebrospinal fluid from the choroid 
plexus, mediated by an increase in IGF-I concentration 
 [33] . The cases identified in this report were reported pre-
viously  [1] . Although most cases of intracranial hyperten-
sion are benign and treatment is straightforward with 
complete reversibility of the increased intracranial pres-
sure, education of both treating physicians and caregivers 
about intracranial hypertension seems essential. Features 
attributable to growth of the nasopharyngeal lymphoid 
tissues were observed as before  [1] . This included snoring 
and hypoacusis. Audiology monitoring predominantly 
revealed intermittent conductive hearing loss with/with-
out decreased tympanic membrane compliance on tym-
panometry (data were not shown). We continued to ob-
serve maturational and coarsening changes in some par-
ticipants’ facial appearance, with the most significant 
changes presenting during puberty  [34] . Although previ-
ously a concern, long-term IGF-I therapy was not accom-
panied by acromegaloid overgrowth of the facial bony 
structures  [35, 36] . Furthermore, the observed soft tissue 
enlargement of the face improved considerably after dis-
continuation of IGF-I therapy.
 In summary, the efficacy and safety of IGF-I therapy 
in patients with severe IGFD has been evaluated for 
 almost two decades. In such patients, IGF-I doses of
120 μg/kg twice daily by subcutaneous injection induce 
significant increases in height velocity and height SD 
score, maintained with prolonged treatment until adult/
near-adult height. Although most subjects do not experi-
ence catch-up growth sufficient to bring their heights into 
the normal range, many patients have achieved an adult 
height significantly greater than expected in the absence 
of therapy. Long-term IGF-I therapy, therefore, appears 
to be effective and relatively safe as a replacement therapy 
in children with short stature due to severe IGFD. The 
availability of IGF-I has been an important development 
for the management of such patients. Because the spec-
trum of GH insensitivity is wider than the patients re-
ported upon in this study, further investigation into the 
therapeutic applicability of IGF-I in patients with varying 
degrees of IGFD is warranted  [37] .
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